VP Research & Academic Affairs, Providence Health Care; President, PHC Research Institute; Associate Dean (Research), UBC Faculty of Medicine
"Elected Fellow." Sindelar R. Canadian Academy of Health Sciences. 2008.
"Friend of Pharmacy Award." Sindelar R. BC Pharmacy Association. 2006.
"Distinguished Alumnus Award." Sindelar R. University of Iowa College of Pharmacy. 2005.
"University of Oklahoma Loyd E. Harris Lecturer." Sindelar R. UO College of Pharmacy. 2005.
"Chair: 3rd AIM Global Deans Forum - The Next FIP Century - Achieving Excellence In Global Pharmacy Education To Meet The Needs Of Society." Sindelar R. 2012 FIP Meeting. Amsterdam, NL. October 2012.
"Meeting Today’s Health Challenges via Academic Redesign." Sindelar R. Universitas 21 AGM 2012. Auckland, NZ. September 2012.
"Redesigning a Faculty of Pharmacy to Meet Today’s Health Challenges." Sindelar R. International Pharmacy Student’s Federation World Congress 2012. Hurghada, EG. August 2012.
"Workshop: Academic Models for Practice Change." Sindelar R. International Pharmacy Student’s Federation World Congress 2012. Hurghada, EG. August 2012.
Dr. Robert Sindelar completed a MSc (1975) and a PhD (1980) in medicinal chemistry and natural products at the University of Iowa. Dr. Sindelar was previously chair and professor of Medicinal Chemistry at the University of Mississippi (1993-2000), as well as the interim dean of the School of Pharmacy and interim executive director of the Research Institute of Pharmaceutical Sciences at the University of Mississippi (2000–2001).
Dr. Sindelar is currently professor and dean emeritus of the Faculty of Pharmaceutical Sciences at UBC. He is also vice president, Research & Academic Affairs at Providence Health Care, president of the PHC Research Institute, and associate dean, Research, at UBC's Faculty of Medicine. His teaching areas of interest include medicinal chemistry, drug discovery and design, and biotechnology as they impact pharmacy practice, patient outcomes and research.
Dr. Sindelar's research areas of interest include natural products isolation, design, synthesis and pharmacological evaluation of potential immunomodulators and agents to combat infectious diseases; rationally-designed enzyme inhibitors; computer-assisted molecular design and computational chemistry; protein homology modeling; and topographical modeling of structurally-rigid natural products and their possible use in immune modulation, microbial chemotherapy, cardiovascular disease, and chemotherapy. Current projects include the optimization of K-76 analogs as immunomodulators of the human complement cascade; and the design of potential inhibitors of human granzyme B.